Development of the optogenetic autoregulated cell transplantation for Parkinson's disease

• Project/Area Number: 18K07509
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52020:Neurology-related
• Research Institution: Juntendo University
• Principal Investigator: Oyama Genko 順天堂大学, 大学院医学研究科, 准教授 (00407256)
• Project Period (FY): 2018-04-01 – 2022-03-31
• Project Status: Completed (Fiscal Year 2021)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: transplantation / iPS cell / Parkinson's disease / optogenetics / ドパミン / 光遺伝学 / iPS細胞 / 移植 / 光刺激

Outline of Final Research Achievements

In this study, we expressed Channelrhodopsin in Human Induced Pluripotent Stem Cells (iPSCs) and differentiated it into dopamine neurons.We confirmed that the neuronal activities of photoreactive dopamine neurons were increased by the blue light and succeeded in finding the adequate condition for phot-stimulation. We studied the potential of Local field potential (LFP) as a biomarker to modulate dopamine neurons. Our result may lead to the development of "the self-regulate dopamine neuron transplantation."

Academic Significance and Societal Importance of the Research Achievements

パーキンソン病患者に対するiPSC由来ドパミン神経細胞移植では、移植片のドパミン放出を制御可能にしない限り、ジスキネジアの問題は解決しないことが予想される。本研究の結果から自律調整性ドパミン神経細胞移植療法がヒトで応用可能になれば、細胞移植療法後に予想されるジスキネジアの問題が解決することが期待できる。

Research Products

• [Presentation] Transplantation of human iPS cell-derived dopamine neural progenitor cells for Parkinson's disease (2019)
  • Author(s): Ryota Nakamura
  • Organizer: 第60回日本神経学会学術大会